Skip to main content

Table 1 Baseline Characteristics of Patients with metastatic melanoma treated in low vs. high immunotherapy prescribing hospitals between 2011 and 2015

From: Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma

 Low prescribing Hospital
N = 997 (53.5%)
High prescribing Hospital
N = 866 (46.5%)
p-value
Age, n (%)< 0.001
  ≤ 3019 (1.9)21 (2.4) 
 31–4041 (4.1)66 (7.6) 
 41–5098 (9.8)105 (12.1) 
 51–60181 (18.2)211 (24.4) 
 61–70286 (28.7)240 (27.7) 
 71–80205 (20.6)149 (17.2) 
 81–90167 (16.8)74 (8.6) 
Gender, n (%)0.430
 Female300 (30.1)277 (32.0) 
 Male697 (69.9)589 (68.0) 
Race, n (%)0.743
 White963 (96.6)832 (96.1) 
 Black13 (1.3)15 (1.7) 
 Other21 (2.1)19 (2.2) 
Year of Diagnosis, n (%)0.481
 2011188 (18.9)176 (20.3) 
 2012186 (18.7)164 (18.9) 
 2013186 (18.7)182 (21.0) 
 2014213 (21.4)175 (20.2) 
 2015224 (22.5)169 (19.5) 
Charlson Deyo Index, n (%)< 0.001
 0740 (74.2)723 (83.5) 
 1183 (18.4)110 (12.7) 
 250 (5.0)24 (2.7) 
  ≥ 324 (2.4)9 (1.0) 
Primary Site, n (%)0.337
 Head and Neck81 (8.1)96 (11.1) 
 Trunk146 (14.6)119 (13.7) 
 Extremities120 (12.0)108 (12.5) 
 overlapping650 (65.2)543 (62.7) 
Histology, n (%)0.035
 Melanoma, NOS874 (87.6)701 (81.0) 
 Nodular49(4.9)76 (8.8) 
 Lentigo5 (0.5)14 (1.6) 
 Superficial spreading25 (2.5)33 (3.8) 
 Acral lentiginous2 (0.2)9 (1.0) 
 other42 (4.2)33 (3.8) 
Metastatic stage, n (%)0.020
 M1, NOS89 (8.9)41 (4.7) 
 M1a136 (13.6)110 (12.7) 
 M1b, lung160 (16.1)105 (12.1) 
 M1c, visceral463 (46.4)530 (61.2) 
 Brain involvement149 (14.9)80 (9.2) 
Ulceration, n (%)0.333
 No ulceration199 (20.0)193 (22.3) 
 Ulceration present135 (13.5)135 (15.6) 
 unknown663 (66.5)538 (62.1) 
Breslow depth (continuous)0.559
 Insurance, n (%)< 0.001
  Private318 (31.9)415 (47.9) 
  Medicare476 (47.7)315 (36.4) 
  Medicaid102 (0.2)55 (6.4) 
  Other Government18 (1.8)10 (1.2) 
  No insurance75 (7.5)26 (3.0) 
  unknown8 (0.8)45 (5.2) 
 Income*, n (%)0.021
   ≥ $ 63,000+319 (32.0)395 (45.6) 
  $ 48,000 – 62,999278 (27.9)238 (27.5) 
  $ 38,000 – 47,999248 (24.9)164 (18.9) 
   < $ 37,000147 (14.7)68 (7.9) 
  unknown5 (0.5)1 (0.1) 
 Education*,**, n (%)< 0.001
   ≥ 21%174 (17.5)84 (9.7) 
 13–20.9%250 (25.1)172 (19.9) 
  7–12.9%347 (34.8)290 (33.5) 
   < 7%223 (22.4)319 (36.8) 
  unknown3 (0.3)1 (0.1) 
 Great Circle Distance, n (%)< 0.001
   < 12.5mi531 (53.3)268 (31.0) 
  12.5–49.9mi352 (35.1)347 (40.1) 
   ≥ 50mi112 (11.2)250 (28.9) 
  unknown2 (0.2)1 (0.1) 
 Facility Location, n (%)0.017
  Northeast121 (12.1)289 (33.4) 
  South509 (51.1)171 (19.8) 
  Midwest90 (9.0)129 (14.9) 
  West222 (22.3)199 (23.0) 
  unknown55 (5.5)78 (9.0) 
 Facility Type, n (%)< 0.001
  Academic324 (34.4)651 (82.6) 
  CCCP472 (50.1)113 (14.3) 
  INCP146 (15.5)24 (3.1) 
 County, n (%)0.637
  Metro838 (84.1)753 (87.0) 
  Urban116 (11.6)89 (9.9) 
  Rural18 (1.8)8 (0.9) 
  unknown25 (2.5)19 (2.2) 
  1. Abbreviations: NOS = not otherwise specified, mi = miles; CCCP = comprehensive community cancer program; INCP = integrated network cancer program
  2. Significant p-values in italic
  3. *ZIP-code level variable
  4. **Percentage of residents in home county with no high school degree from 2012 American County Survey Data